Short Interest in Spectral Diagnostics Inc. (OTCMKTS:EDTXF) Drops By 37.9%

Spectral Diagnostics Inc. (OTCMKTS:EDTXF) was the target of a large decrease in short interest in the month of July. As of July 15th, there was short interest totaling 6,242 shares, a decrease of 37.9% from the June 30th total of 10,049 shares. Approximately 0.0% of the shares of the company are sold short. Based on an average trading volume of 12,727 shares, the short-interest ratio is presently 0.5 days.

Spectral Diagnostics Stock Down 0.6%

Shares of OTCMKTS EDTXF traded down $0.01 during trading on Friday, reaching $0.99. 2,200 shares of the company traded hands, compared to its average volume of 9,067. The firm has a 50 day simple moving average of $0.98 and a 200-day simple moving average of $0.99. The stock has a market capitalization of $290.32 million, a PE ratio of -9.89 and a beta of 0.11. Spectral Diagnostics has a 52-week low of $0.58 and a 52-week high of $1.31.

Spectral Diagnostics (OTCMKTS:EDTXF) last released its quarterly earnings data on Friday, May 8th. The company reported ($0.01) earnings per share for the quarter, meeting the consensus estimate of ($0.01). The company had revenue of $0.64 million for the quarter, compared to analysts’ expectations of $0.54 million.

Spectral Diagnostics Company Profile

Spectral Medical Inc focuses on the development and commercialization of products for the treatment of septic shock in the United States, Italy, Ireland, and internationally. The company markets Endotoxin Activity Assay, a rapid in vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops and manufactures monoclonal and polyclonal antibodies, recombinant cardiac proteins, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies.